EuBiologics Co., Ltd.
KOSDAQ-listed vaccine maker supplying oral cholera vaccine to UNICEF alongside a biologics CRMO business.
As of 2026-10-10, EuBiologics Co., Ltd. has 4 Korean MFDS device approvals, 5 Korean MFDS drug approvals, 36 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KOSDAQ in 2017, EuBiologics specializes in vaccine development and supply as well as biologics CRMO (contract research and manufacturing) services. It supplies oral cholera vaccine to UNICEF and is pursuing follow-on vaccines such as typhoid and meningococcal vaccines, along with premium vaccines targeting developed markets. Its 2025 cholera vaccine revenue reached KRW 145.2 billion, growing more than 30% annually, while its CRMO business maintains annual revenue of KRW 3-6 billion.
Products & technology
- Oral cholera vaccineCholera prevention vaccine supplied to UNICEF
- CRMO (Contract Research and Manufacturing Organization) servicesContract research and manufacturing for biologics
Regulatory approvals
data.go.kr5 Korean MFDS drug approvals · 2015–2025 / 4 Korean MFDS device approvals · 2020–2021
- MFDS drugEuTYPH-C Inj. Multi-dose(Typhoid Purified Vi Polysaccharide Conjugated to Diphtheria CRM197 Vaccine)2025-07-30Drug · Prescription · Approval202501995
- MFDS drugEuvichol-S2023-12-19Drug · Prescription · Approval202303370
- MFDS drugEuCorVac-19 Inj. Multi-dose(SARS-CoV-2 Spike Protein Vaccine(Recombinant))2023-01-30Drug · Prescription · Approval202300374
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2021-01-28Product approval · Class 3체외 제허 21-72 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2020-11-19Product approval · Class 3체외 제허 20-980 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-09-17Product approval · Class 3체외 제허 20-818 호
- MFDSBandage, compressionRevoked2020-05-26Product approval · Class 1제신 20-718 호
- MFDS drugEuvichol-Plus2017-03-29Drug · Prescription · Approval201701512
- MFDS drugEuvichol2015-01-28Drug · Prescription · Approval201500462
Clinical trials
data.go.kr12 MFDS clinical trial authorisations · 2012–2025 (Phase 1 8 · Phase 1/2 3 · Phase 3 1)
- Phase 1mCOV백신(사스코로나바이러스-2 mRNA 백신)2025-12-23
- Phase 1EuHZV(유바이오로직스 대상포진 백신)2024-04-19
1 trial site
- Phase 1호흡기세포융합바이러스 백신(RSV vaccine)2024-01-02
1 trial site
- Phase 1/2유코백-19(EuCorVac-19)2022-12-06
1 trial site
- Phase 1EuCCV주/EuCCV-AL주2022-04-15
3 trial sites
- Phase 3유코백-19(EuCorVac-19)2022-01-28
1 trial site
- Phase 1/2유코백-19(EuCorVac-19)2021-01-20
5 trial sites
- Phase 1EuMCV5주2021-01-06
1 trial site
- Phase 1EuMCV4주2020-06-11
1 trial site
- Phase 1EuPCV15주 (폐렴구균-디프테리아 CRM197단백 접합 백신)2019-10-01
1 trial site
- Phase 1/2ATGC-100주2019-03-19
1 trial site
- Phase 1유비콜2012-07-31
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Active not recruiting · 2024-07 · NCT06409494
Phase 1 · Active not recruiting · 2024-05 · NCT06216093
Phase 1 · Completed · 2023-02 · NCT05739292
Phase 3 · Completed · 2022-10 · NCT05572879
Phase 3 · Completed · 2022-07 · NCT05603052
- Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults
Phase 1/2 · Completed · 2021-02 · NCT04783311
Phase 2/3 · Completed · 2020-09 · NCT04830371
Phase 1 · Completed · 2020-09 · NCT04714229
Phase 3 · Completed · 2020-06 · NCT04830345
Phase 1 · Completed · 2020-05 · NCT04830358
Show 4 more trials
Phase 1/2 · Completed · 2019-04 · NCT03970876
Phase 1 · Completed · 2019-03 · NCT03956524
Phase 3 · Completed · 2014-05 · NCT02164110
Phase 1 · Completed · 2012-09 · NCT01707537
R&D and key agreements
Source: DART corporate disclosure장티푸스 백신 · 장티푸스 · 개발중 · Follow-on vaccine pipeline after cholera vaccine
수막구균 백신 · 수막구균 감염증 · 개발중
프리미엄 백신 · 개발중 · Premium vaccine targeting developed markets
Key disclosures
KRX KIND via OpenDARTShow 10 more events
Publications
PubMed · affiliation-matched- Recombinant Japanese Encephalitis Virus Envelope Antigen Presented on CoPoP Liposomes Elicits Cellular Immunity and Protects Mice From Lethal Challenge.
Immune network · 2026-04 · Kim SY, Jung IR, Park H 외 16
- Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.
The Lancet. Global health · 2025-12 · Ndiaye BP, Koech L, Mercer LD 외 20
- Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos.
Vaccines · 2025-07 · Lovell JF, Miura K, Baik YO 외 11
- Intranasal vaccines adjuvanted with Nexavant demonstrate robust protective efficacy by inducing both mucosal and systemic immunity in a murine model.
Frontiers in immunology · 2025-01 · Ko KH, Bae HS, Lee SM 외 7
- Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
Journal of medical virology · 2024-09 · Lovell JF, Miura K, Baik YO 외 10
- Author Correction: A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine.
NPJ vaccines · 2024-09 · Kim Y, Bae S, Yu KS 외 5
- A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine.
NPJ vaccines · 2024-08 · Kim Y, Bae S, Yu KS 외 5
- Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
The Lancet. Global health · 2024-05 · Song KR, Chapagain RH, Tamrakar D 외 24
- Engineering Escherichia coli for constitutive production of monophosphoryl lipid A vaccine adjuvant.
Biotechnology and bioengineering · 2024-03 · Jin H, Ji Y, An J 외 10
- One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024-01 · Lovell JF, Miura K, Baik YO 외 14
Show 26 more publications
- Vaccine traceability: Key learnings from the supply chain initiative by manufacturers from emerging countries.
Vaccine: X · 2023-12 · Pagliusi S, Madrid Y, Bramanti Y 외 8
- Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.
The Lancet regional health. Southeast Asia · 2023-12 · Shah S, Nandy RK, Sethi SS 외 18
- Vaccination of Rabbits with a Cholera Conjugate Vaccine Comprising O-Specific Polysaccharide and a Recombinant Fragment of Tetanus Toxin Heavy Chain Induces Protective Immune Responses against Vibrio cholerae O1.
The American journal of tropical medicine and hygiene · 2023-11 · Kelly M, Jeon S, Yun J 외 15
- Production of Plant-Derived Japanese Encephalitis Virus Multi-Epitope Peptide in Nicotiana benthamiana and Immunological Response in Mice.
International journal of molecular sciences · 2023-07 · Jung JW, Park PG, Lee WK 외 10
- Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.
Vaccine · 2023-04 · Riddle MS, Louis Bourgeois A, Clifford A 외 6
- A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
Vaccine · 2023-03 · Ok Baik Y, Lee Y, Lee C 외 11
- 30-Minute Highly Multiplexed VaxArray Immunoassay for Pneumococcal Vaccine Antigen Characterization.
Vaccines · 2022-11 · Hu T, Miller DF, Taylor AW 외 9
- Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.
BMC medicine · 2022-11 · Lovell JF, Baik YO, Choi SK 외 14
- The importance of vaccine stockpiling to respond to epidemics and remediate global supply shortages affecting immunization: strategic challenges and risks identified by manufacturers.
Vaccine: X · 2021-12 · Jarrett S, Pagliusi S, Park R 외 5
- Scalable production and immunogenicity of a cholera conjugate vaccine.
Vaccine · 2021-11 · Jeon S, Kelly M, Yun J 외 20
- An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
Vaccine · 2021-05 · Choi SK, Baik YO, Kim CW 외 5
- Assignment of opsonic values to pneumococcal reference serum 007sp and a second pneumococcal OPA calibration serum panel (Ewha QC sera panel B) for 11 serotypes.
Vaccine · 2020-12 · Burton RL, Kim HW, Lee S 외 13
- Generation and Characterization of Monoclonal Antibodies to the Ogawa Lipopolysaccharide of Vibrio cholerae O1 from Phage-Displayed Human Synthetic Fab Library.
Journal of microbiology and biotechnology · 2020-11 · Kim D, Hong J, Choi Y 외 8
- Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
Vaccine · 2020-07 · Pagliusi S, Jarrett S, Hayman B 외 14
- E. coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine.
Vaccines · 2020-06 · Nguyen QT, Kim E, Yang J 외 5
- WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019.
Biologicals : journal of the International Association of Biological Standardization · 2020-05 · Wadhwa M, Kang HN, Jivapaisarnpong T 외 55
- Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant.
Metabolic engineering · 2020-01 · Ji Y, An J, Hwang D 외 8
- Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.
PloS one · 2020-01 · Whang YH, Kim SK, Yoon H 외 4
- Quality Improvement of Capsular Polysaccharide in Streptococcus pneumoniae by Purification Process Optimization.
Frontiers in bioengineering and biotechnology · 2020-01 · Lee C, Chun HJ, Park M 외 6
- Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity.
Biologicals : journal of the International Association of Biological Standardization · 2019-09 · Lee C, Choi SK, Kim RK 외 9
- Generation of a Human Monoclonal Antibody to Cross-Reactive Material 197 (CRM₁₉₇) and Development of a Sandwich ELISA for CRM₁₉₇ Conjugate Vaccines.
Journal of microbiology and biotechnology · 2018-12 · Kim D, Yoon H, Kim S 외 8
- The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships.
Vaccine · 2018-10 · Odevall L, Hong D, Digilio L 외 6
- A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
Vaccine · 2018-07 · Russo P, Ligsay AD, Olveda R 외 13
- Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model.
Clinical and experimental vaccine research · 2018-07 · Lee EY, Lee S, Rho S 외 6
- A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Vaccine · 2015-11 · Baik YO, Choi SK, Olveda RM 외 12
- A 6-week oral toxicity study of oral cholera vaccine in sprague-dawley rats.
Toxicological research · 2012-12 · Baek YO, Choi SK, Shin SH 외 12
Patents
KIPRIS · applicant-matchedUS · Published · 2025-09 · Application 19331238
US · Published · 2023-10 · Application 18495475
Published · 2023-10 · Application 1020230145102
US · Registered · 2021-09 · Application 18023580
EP · Published · 2021-09 · Application 21867042.0
PCT · Published · 2021-09 · Application PCT/KR2021/011841
Registered · 2021-09 · Application 1020210117104
Withdrawn · 2021-03 · Application 1020210042289
US · Registered · 2020-08 · Application 17630657
PCT · Published · 2020-08 · Application PCT/KR2020/011425
Show 15 more patents
Registered · 2020-08 · Application 1020200107412
Registered · 2019-12 · Application 1020190160771
US · Registered · 2019-10 · Application 17638822
EP · Published · 2019-10 · Application 24182153.7
EP · Published · 2019-10 · Application 19944515.6
PCT · Published · 2019-10 · Application PCT/KR2019/012899
Registered · 2019-09 · Application 1020190108892
PCT · Published · 2019-07 · Application PCT/KR2019/008646
PCT · Published · 2019-07 · Application PCT/KR2019/008113
Rejected · 2019-07 · Application 1020190079797
Registered · 2018-12 · Application 1020180154482
Registered · 2018-07 · Application 1020180082324
Expired · 2018-03 · Application 1020180036132
Registered · 2017-04 · Application 1020170054487
Withdrawn · 2016-10 · Application 1020160136043
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive3
- OpenAIOAI-SearchBot45
- PerplexityPerplexityBot2
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for EuBiologics Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Founded 2007, KOSDAQ-listed 2023, SLSBio provides pharmaceutical quality control, drug development support, and in vitro diagnostics.
Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Founded in 1966, KOSPI-listed PharmGen Science makes GI and cardiovascular prescription drugs plus health foods and beauty products.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition